PUBLISHER: 360iResearch | PRODUCT CODE: 1613436
PUBLISHER: 360iResearch | PRODUCT CODE: 1613436
Down Syndrome Market by Offering (Assistive Devices, Medications), Disease Type (Mosaic Down Syndrome, Translocation, Trisomy 21), Type, End-User - Global Forecast 2025-2030
The Down Syndrome Market was valued at USD 1.89 billion in 2023, expected to reach USD 2.02 billion in 2024, and is projected to grow at a CAGR of 7.44%, to USD 3.12 billion by 2030.
Down Syndrome, a genetic disorder caused by the presence of an extra chromosome 21, affects cognitive and physical development and is the focus of various market opportunities within the healthcare and wellness sectors. The necessity for research and application in this sphere is borne from the absence of a cure, which propels the market toward the development of therapeutic interventions, early diagnostic tools, and educational and support services. The end-use scope ranges from healthcare providers and families to academic researchers and governmental bodies, keen on enhancing support infrastructures and reducing the associated healthcare costs. Market growth is significantly influenced by the increasing adoption of non-invasive prenatal testing (NIPT) and a shift towards personalized medicine and genetic counseling services. Furthermore, awareness campaigns advocating early intervention and comprehensive care have significantly increased service adoption rates. However, challenges include high costs of treatment and care, lack of awareness in developing regions, and ethical concerns regarding prenatal screening. Opportunities abound in the development of advanced assistive technologies, behavioral therapy innovations, and mobile health applications designed to support those with Down Syndrome and their families in daily management and learning activities. The market may also leverage big data analytics and artificial intelligence to improve care strategies and predict health outcomes. Moreover, innovation in diagnostic technologies and targeted biotech research offers promising avenues for specialized treatment development. However, market players must navigate regulatory hurdles and invest in community education to enhance perception and quality of care. Strategically harnessing partnerships between biotech companies and healthcare providers can further propel market growth while ensuring access and equality in care, making it an attractive yet complex landscape for investment and development in the coming years.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2023] | USD 1.89 billion |
| Estimated Year [2024] | USD 2.02 billion |
| Forecast Year [2030] | USD 3.12 billion |
| CAGR (%) | 7.44% |
Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Down Syndrome Market
The Down Syndrome Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.
- Market Drivers
- Increasing prevalence and diagnosis rates of Down syndrome
- Implementation of government policies to support access to Down syndrome medications
- Preference for specialized assistive technologies to treat Down syndrome
- Market Restraints
- High cost of advanced therapies and diagnostic tools
- Market Opportunities
- Technological advancements in genetic testing and screening tools
- Government funding for Down syndrome research with supportive awareness programs
- Market Challenges
- Limited standardization and unavailability of appropriate approved treatments for Down syndrome
Porter's Five Forces: A Strategic Tool for Navigating the Down Syndrome Market
Porter's five forces framework is a critical tool for understanding the competitive landscape of the Down Syndrome Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.
PESTLE Analysis: Navigating External Influences in the Down Syndrome Market
External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Down Syndrome Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.
Market Share Analysis: Understanding the Competitive Landscape in the Down Syndrome Market
A detailed market share analysis in the Down Syndrome Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.
FPNV Positioning Matrix: Evaluating Vendors' Performance in the Down Syndrome Market
The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Down Syndrome Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.
Strategy Analysis & Recommendation: Charting a Path to Success in the Down Syndrome Market
A strategic analysis of the Down Syndrome Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.
Key Company Profiles
The report delves into recent significant developments in the Down Syndrome Market, highlighting leading vendors and their innovative profiles. These include AC Immune SA, Aelis Farma, Agilent Technologies, Inc., Alzheon, Inc., Annovis Bio, Aphios Corporation, Avanti Biosciences Inc. by Solid Biosciences Inc., Bio-Rad Laboratories, Inc., Demeditec Diagnostics GmbH, Elixirgen Therapeutics, Inc., Illumina, Inc., Inspire Medical Systems, Inc., KinoPharma, Inc., Laboratory Corporation of America Holdings, LifeCell International Private Limited by Allergan PLC, Lilac Insights Pvt. Ltd., Myriad Genetics, Inc., Natera, Inc., NeuroNascent, Inc., OPKO Health, Inc., Pharmasum Therapeutics, Quest Diagnostics Incorporated, Roche Diagnostics Corporation, Strand Life Sciences by Reliance Industries Ltd., and Yourgene Health by Novacyt Group.
Market Segmentation & Coverage
This research report categorizes the Down Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Based on Offering, market is studied across Assistive Devices and Medications.
- Based on Disease Type, market is studied across Mosaic Down Syndrome, Translocation, and Trisomy 21.
- Based on Type, market is studied across Postnatal Testing and Prenatal Testing.
- Based on End-User, market is studied across Homecare Setting, Hospital & Clinics, and Therapy Centers.
- Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
The report offers a comprehensive analysis of the market, covering key focus areas:
1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.
2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.
3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.
4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.
5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.
The report also answers critical questions to aid stakeholders in making informed decisions:
1. What is the current market size, and what is the forecasted growth?
2. Which products, segments, and regions offer the best investment opportunities?
3. What are the key technology trends and regulatory influences shaping the market?
4. How do leading vendors rank in terms of market share and competitive positioning?
5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Increasing prevalence and diagnosis rates of Down syndrome
- 5.1.1.2. Implementation of government policies to support access to Down syndrome medications
- 5.1.1.3. Preference for specialized assistive technologies to treat Down syndrome
- 5.1.2. Restraints
- 5.1.2.1. High cost of advanced therapies and diagnostic tools
- 5.1.3. Opportunities
- 5.1.3.1. Technological advancements in genetic testing and screening tools
- 5.1.3.2. Government funding for Down syndrome research with supportive awareness programs
- 5.1.4. Challenges
- 5.1.4.1. Limited standardization and unavailability of appropriate approved treatments for Down syndrome
- 5.1.1. Drivers
- 5.2. Market Segmentation Analysis
- 5.2.1. Offering: Need for assistive devices to address a broad range of needs that can change as the patient ages
- 5.2.2. End-User: Crucial role played by hospitals & clinics in providing a broad range of medical services for diagnosing, treating, and managing Down Syndrome
- 5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
- 5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental
6. Down Syndrome Market, by Offering
- 6.1. Introduction
- 6.2. Assistive Devices
- 6.3. Medications
7. Down Syndrome Market, by Disease Type
- 7.1. Introduction
- 7.2. Mosaic Down Syndrome
- 7.3. Translocation
- 7.4. Trisomy 21
8. Down Syndrome Market, by Type
- 8.1. Introduction
- 8.2. Postnatal Testing
- 8.3. Prenatal Testing
9. Down Syndrome Market, by End-User
- 9.1. Introduction
- 9.2. Homecare Setting
- 9.3. Hospital & Clinics
- 9.4. Therapy Centers
10. Americas Down Syndrome Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
11. Asia-Pacific Down Syndrome Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.10. South Korea
- 11.11. Taiwan
- 11.12. Thailand
- 11.13. Vietnam
12. Europe, Middle East & Africa Down Syndrome Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.10. Nigeria
- 12.11. Norway
- 12.12. Poland
- 12.13. Qatar
- 12.14. Russia
- 12.15. Saudi Arabia
- 12.16. South Africa
- 12.17. Spain
- 12.18. Sweden
- 12.19. Switzerland
- 12.20. Turkey
- 12.21. United Arab Emirates
- 12.22. United Kingdom
13. Competitive Landscape
- 13.1. Market Share Analysis, 2023
- 13.2. FPNV Positioning Matrix, 2023
- 13.3. Competitive Scenario Analysis
- 13.3.1. Innovative Prenatal Screening Technologies Launched by Strand Life Sciences
- 13.3.2. Launch of Non-Invasive Prenatal Testing in Morocco by Yourgene Health and Laboriad
- 13.3.3. FDA Approves Inspire Therapy for Teens with Down Syndrome and Severe OSA
- 13.4. Strategy Analysis & Recommendation
Companies Mentioned
- 1. AC Immune SA
- 2. Aelis Farma
- 3. Agilent Technologies, Inc.
- 4. Alzheon, Inc.
- 5. Annovis Bio
- 6. Aphios Corporation
- 7. Avanti Biosciences Inc. by Solid Biosciences Inc.
- 8. Bio-Rad Laboratories, Inc.
- 9. Demeditec Diagnostics GmbH
- 10. Elixirgen Therapeutics, Inc.
- 11. Illumina, Inc.
- 12. Inspire Medical Systems, Inc.
- 13. KinoPharma, Inc.
- 14. Laboratory Corporation of America Holdings
- 15. LifeCell International Private Limited by Allergan PLC
- 16. Lilac Insights Pvt. Ltd.
- 17. Myriad Genetics, Inc.
- 18. Natera, Inc.
- 19. NeuroNascent, Inc.
- 20. OPKO Health, Inc.
- 21. Pharmasum Therapeutics
- 22. Quest Diagnostics Incorporated
- 23. Roche Diagnostics Corporation
- 24. Strand Life Sciences by Reliance Industries Ltd.
- 25. Yourgene Health by Novacyt Group
LIST OF FIGURES
- FIGURE 1. DOWN SYNDROME MARKET RESEARCH PROCESS
- FIGURE 2. DOWN SYNDROME MARKET SIZE, 2023 VS 2030
- FIGURE 3. GLOBAL DOWN SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. GLOBAL DOWN SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 5. GLOBAL DOWN SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. GLOBAL DOWN SYNDROME MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
- FIGURE 7. GLOBAL DOWN SYNDROME MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 8. GLOBAL DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
- FIGURE 9. GLOBAL DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 10. GLOBAL DOWN SYNDROME MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
- FIGURE 11. GLOBAL DOWN SYNDROME MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 12. GLOBAL DOWN SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
- FIGURE 13. GLOBAL DOWN SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 14. AMERICAS DOWN SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 15. AMERICAS DOWN SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 16. UNITED STATES DOWN SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 17. UNITED STATES DOWN SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 18. ASIA-PACIFIC DOWN SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 19. ASIA-PACIFIC DOWN SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DOWN SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DOWN SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 22. DOWN SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
- FIGURE 23. DOWN SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
- TABLE 1. DOWN SYNDROME MARKET SEGMENTATION & COVERAGE
- TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
- TABLE 3. GLOBAL DOWN SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
- TABLE 4. GLOBAL DOWN SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
- TABLE 5. GLOBAL DOWN SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 6. DOWN SYNDROME MARKET DYNAMICS
- TABLE 7. GLOBAL DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 8. GLOBAL DOWN SYNDROME MARKET SIZE, BY ASSISTIVE DEVICES, BY REGION, 2018-2030 (USD MILLION)
- TABLE 9. GLOBAL DOWN SYNDROME MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 10. GLOBAL DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 11. GLOBAL DOWN SYNDROME MARKET SIZE, BY MOSAIC DOWN SYNDROME, BY REGION, 2018-2030 (USD MILLION)
- TABLE 12. GLOBAL DOWN SYNDROME MARKET SIZE, BY TRANSLOCATION, BY REGION, 2018-2030 (USD MILLION)
- TABLE 13. GLOBAL DOWN SYNDROME MARKET SIZE, BY TRISOMY 21, BY REGION, 2018-2030 (USD MILLION)
- TABLE 14. GLOBAL DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 15. GLOBAL DOWN SYNDROME MARKET SIZE, BY POSTNATAL TESTING, BY REGION, 2018-2030 (USD MILLION)
- TABLE 16. GLOBAL DOWN SYNDROME MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2030 (USD MILLION)
- TABLE 17. GLOBAL DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 18. GLOBAL DOWN SYNDROME MARKET SIZE, BY HOMECARE SETTING, BY REGION, 2018-2030 (USD MILLION)
- TABLE 19. GLOBAL DOWN SYNDROME MARKET SIZE, BY HOSPITAL & CLINICS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 20. GLOBAL DOWN SYNDROME MARKET SIZE, BY THERAPY CENTERS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 21. AMERICAS DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 22. AMERICAS DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 23. AMERICAS DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 24. AMERICAS DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 25. AMERICAS DOWN SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 26. ARGENTINA DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 27. ARGENTINA DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 28. ARGENTINA DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 29. ARGENTINA DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 30. BRAZIL DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 31. BRAZIL DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 32. BRAZIL DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 33. BRAZIL DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 34. CANADA DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 35. CANADA DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 36. CANADA DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 37. CANADA DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 38. MEXICO DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 39. MEXICO DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 40. MEXICO DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 41. MEXICO DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 42. UNITED STATES DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 43. UNITED STATES DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 44. UNITED STATES DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 45. UNITED STATES DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 46. UNITED STATES DOWN SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
- TABLE 47. ASIA-PACIFIC DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 48. ASIA-PACIFIC DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 49. ASIA-PACIFIC DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 50. ASIA-PACIFIC DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 51. ASIA-PACIFIC DOWN SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 52. AUSTRALIA DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 53. AUSTRALIA DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 54. AUSTRALIA DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 55. AUSTRALIA DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 56. CHINA DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 57. CHINA DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 58. CHINA DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 59. CHINA DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 60. INDIA DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 61. INDIA DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 62. INDIA DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 63. INDIA DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 64. INDONESIA DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 65. INDONESIA DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 66. INDONESIA DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 67. INDONESIA DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 68. JAPAN DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 69. JAPAN DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 70. JAPAN DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 71. JAPAN DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 72. MALAYSIA DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 73. MALAYSIA DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 74. MALAYSIA DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 75. MALAYSIA DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 76. PHILIPPINES DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 77. PHILIPPINES DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 78. PHILIPPINES DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 79. PHILIPPINES DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 80. SINGAPORE DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 81. SINGAPORE DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 82. SINGAPORE DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 83. SINGAPORE DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 84. SOUTH KOREA DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 85. SOUTH KOREA DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 86. SOUTH KOREA DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 87. SOUTH KOREA DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 88. TAIWAN DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 89. TAIWAN DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 90. TAIWAN DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 91. TAIWAN DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 92. THAILAND DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 93. THAILAND DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 94. THAILAND DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 95. THAILAND DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 96. VIETNAM DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 97. VIETNAM DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 98. VIETNAM DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 99. VIETNAM DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 100. EUROPE, MIDDLE EAST & AFRICA DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 101. EUROPE, MIDDLE EAST & AFRICA DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 102. EUROPE, MIDDLE EAST & AFRICA DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 103. EUROPE, MIDDLE EAST & AFRICA DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 104. EUROPE, MIDDLE EAST & AFRICA DOWN SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 105. DENMARK DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 106. DENMARK DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 107. DENMARK DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 108. DENMARK DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 109. EGYPT DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 110. EGYPT DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 111. EGYPT DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 112. EGYPT DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 113. FINLAND DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 114. FINLAND DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 115. FINLAND DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 116. FINLAND DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 117. FRANCE DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 118. FRANCE DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 119. FRANCE DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 120. FRANCE DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 121. GERMANY DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 122. GERMANY DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 123. GERMANY DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 124. GERMANY DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 125. ISRAEL DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 126. ISRAEL DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 127. ISRAEL DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 128. ISRAEL DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 129. ITALY DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 130. ITALY DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 131. ITALY DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 132. ITALY DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 133. NETHERLANDS DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 134. NETHERLANDS DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 135. NETHERLANDS DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 136. NETHERLANDS DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 137. NIGERIA DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 138. NIGERIA DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 139. NIGERIA DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 140. NIGERIA DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 141. NORWAY DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 142. NORWAY DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 143. NORWAY DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 144. NORWAY DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 145. POLAND DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 146. POLAND DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 147. POLAND DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 148. POLAND DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 149. QATAR DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 150. QATAR DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 151. QATAR DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 152. QATAR DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 153. RUSSIA DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 154. RUSSIA DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 155. RUSSIA DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 156. RUSSIA DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 157. SAUDI ARABIA DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 158. SAUDI ARABIA DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 159. SAUDI ARABIA DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 160. SAUDI ARABIA DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 161. SOUTH AFRICA DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 162. SOUTH AFRICA DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 163. SOUTH AFRICA DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 164. SOUTH AFRICA DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 165. SPAIN DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 166. SPAIN DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 167. SPAIN DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 168. SPAIN DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 169. SWEDEN DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 170. SWEDEN DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 171. SWEDEN DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 172. SWEDEN DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 173. SWITZERLAND DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 174. SWITZERLAND DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 175. SWITZERLAND DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 176. SWITZERLAND DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 177. TURKEY DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 178. TURKEY DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 179. TURKEY DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 180. TURKEY DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 181. UNITED ARAB EMIRATES DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 182. UNITED ARAB EMIRATES DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 183. UNITED ARAB EMIRATES DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 184. UNITED ARAB EMIRATES DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 185. UNITED KINGDOM DOWN SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
- TABLE 186. UNITED KINGDOM DOWN SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 187. UNITED KINGDOM DOWN SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 188. UNITED KINGDOM DOWN SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 189. DOWN SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
- TABLE 190. DOWN SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023
